Quarterly report pursuant to Section 13 or 15(d)

INVESTMENT (Details Narrative)

v3.21.2
INVESTMENT (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Mar. 12, 2021
Sep. 30, 2021
Sep. 30, 2021
Defined Benefit Plan Disclosure [Line Items]      
Aggregrate investment   $ 6,000,000 $ 6,000,000
Equity investment   5,000,000 5,000,000
Convertable note investment   1,000,000 1,000,000
Iliad [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Aggregrate investment   6,000,000 6,000,000
Equity investment   5,000,000 5,000,000
Equity investment - net loss   $ 186,000 $ 632,000
Iliad [Member] | Class C Units [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Ownership percentage not fully diluted   9.50% 9.50%
Ownership percentage fully diluted   7.30% 7.30%
I Liad Biotechnologies L L C [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Additional convertable note investment $ 1,000,000    
Maximum convertible debt offering $ 23,500,000    
Interest rate 6.00%    
Notes conversion, description The Notes are required to be converted into a Qualified Financing (minimum financing of $15 million) at the lesser of (i) 80% of the price paid per unit in such offering or (ii) a price based on an enterprise value of $176,000,000. In addition, the Notes shall convert in the event of a merger at the lower of an enterprise value of $176,000,000 or the stated valuation of ILiAD in the merger transaction